Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy

In breast cancer patients, primary chemotherapy is associated with the same survival benefits as adjuvant chemotherapy. Residual tumors represent a clinical challenge, as they may be resistant to additional cycles of the same drugs. Our aim was to identify differential transcripts expressed in resid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology reports 2009-10, Vol.22 (4), p.805-813
Hauptverfasser: AZEVEDO KOIKE FOLGUEIRA, Maria Aparecida, BRENTANI, Helena, MOURAO, Mario, FIGARO CALDEIRA, José Roberto, MITZI BRENTANI, Maria, CARRARO, Dirce Maria, DE CAMARGO BARROS, Mateus, HIRATA KATAYAMA, Maria Lucia, SANTANA DE ABREU, Ana Paula, MANTOVANI BARBOSA, Edson, TOSELLO DE OLIVEIRA, Celia, PATRAO, Diogo F. C, MOTA, Louise D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In breast cancer patients, primary chemotherapy is associated with the same survival benefits as adjuvant chemotherapy. Residual tumors represent a clinical challenge, as they may be resistant to additional cycles of the same drugs. Our aim was to identify differential transcripts expressed in residual tumors, after neoadjuvant chemotherapy, that might be related with tumor resistance. Hence, 16 patients with paired tumor samples, collected before and after treatment (4 cycles doxorubicin/cyclophosphamide, AC) had their gene expression evaluated on cDNA microarray slides containing 4,608 genes. Three hundred and eighty-nine genes were differentially expressed (paired Student's t-test, pFDR
ISSN:1021-335X
1791-2431
DOI:10.3892/or_00000503